Eltrombopag olamine (Revolade)
The objective of this review was to perform a systematic review to evaluate the beneficial and harmful effects of eltrombopag 25 mg and 50 mg tablets used in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) to increase platelet counts in patients with thrombocytopenia (TCP) and ch...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review to evaluate the beneficial and harmful effects of eltrombopag 25 mg and 50 mg tablets used in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) to increase platelet counts in patients with thrombocytopenia (TCP) and chronic hepatitis C virus (HCV) infection to allow the initiation and maintenance of IFN-based therapy |
|---|---|
| Physical Description: | 1 PDF file illustration |